| Literature DB >> 34245910 |
Michel L Leite1, Lorena S de Loiola Costa2, Victor A Cunha2, Victor Kreniski3, Mario de Oliveira Braga Filho3, Nicolau B da Cunha2, Fabricio F Costa4.
Abstract
Over the past few decades, the number of health and 'omics-related data' generated and stored has grown exponentially. Patient information can be collected in real time and explored using various artificial intelligence (AI) tools in clinical trials; mobile devices can also be used to improve aspects of both the diagnosis and treatment of diseases. In addition, AI can be used in the development of new drugs or for drug repurposing, in faster diagnosis and more efficient treatment for various diseases, as well as to identify data-driven hypotheses for scientists. In this review, we discuss how AI is starting to revolutionize the life sciences sector.Entities:
Keywords: Artificial intelligence (AI); Big data analytics; Clinical trials; Diseases; Life sciences; Machine learning (ML); Mobile technologies; Patient-centric solutions
Mesh：
Year: 2021 PMID： 34245910 DOI： 10.1016/j.drudis.2021.07.002
Source DB: PubMed Journal: Drug Discov Today ISSN： 1359-6446 Impact factor: 7.851